Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07OAD
|
|||
| Former ID |
DNCL002383
|
|||
| Drug Name |
GO-203-2c
|
|||
| Indication | Acute myeloid leukaemia [ICD-11: 2A60] | Phase 2 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-9: 140-199, 210-229] | Phase 1/2 | [2] | ||
| Company |
Genus Oncology
|
|||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mucin-1 (MUC1) | Target Info | Inhibitor | [3] |
| WikiPathways | Hematopoietic Stem Cell Differentiation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT02204085) A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of Genus Oncology. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.